Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | BUB1 | O43683 | 11/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882437 | 0.78 | CYP19A1 (0.40) | KMT2AKDM4ENAMPTALDH1A1GLA | |
| SCHEMBL2880406 | 0.76 | KDM4E (0.47) | KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL30047093 | 0.74 | KMT2A (0.50) | KMT2AKDM4EBUB1NAMPTLATS1 | |
| SCHEMBL2885166 | 0.73 | NAMPT (0.45) | KMT2ANAMPT | |
| SCHEMBL2885164 | 0.71 | OPRL1 (0.48) | KMT2ANAMPT | |
| SCHEMBL26120276 | 0.70 | MAPT (0.37) | KMT2AKDM4ENAMPTALDH1A1GAA | |
| SCHEMBL924439 | 0.70 | CYP19A1 (0.46) | ALDH1A1CYP19A1 | |
| SCHEMBL5347045 | 0.69 | KMT2A (0.40) | KMT2AKDM4EBUB1ALDH1A1GAA | |
| SCHEMBL4432302 | 0.69 | MTNR1A (0.53) | KMT2AALDH1A1 | |
| SCHEMBL29882799 | 0.69 | MTNR1A (0.53) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | KMT2A 2466/4885KDM4E 3605/4885BUB1 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.